Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UMPS | P11172 | 5/20 | 0.49 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.47 |
| ▸ | ATIC | P31939 | 2/20 | 0.46 |
| ▸ | GART | P22102 | 1/20 | 0.46 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.45 |
| ▸ | FBP1 | P09467 | 2/20 | 0.45 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.44 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.44 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31685165 | 0.83 | ADORA1 (0.39) | — | |
| SCHEMBL31685237 | 0.83 | CDA (0.43) | — | |
| SCHEMBL20305094 | 0.82 | UMPS (0.51) | UMPSDNPH1ATICP2RY2FBP1 | |
| SCHEMBL31685288 | 0.82 | UMPS (0.47) | UMPSDNPH1ATICP2RY2FBP1 | |
| SCHEMBL31685177 | 0.82 | UMPS (0.51) | UMPSDNPH1ATICP2RY2FBP1 | |
| SCHEMBL31685198 | 0.81 | TYMS (0.48) | — | |
| SCHEMBL31685179 | 0.79 | UMPS (0.45) | UMPSDNPH1ATICGARTP2RY2 | |
| SCHEMBL31685543 | 0.77 | UMPS (0.48) | UMPSDNPH1ATICGARTP2RY2 | |
| SCHEMBL6465100 | 0.73 | P2RY2 (0.49) | P2RY2P2RY6 | |
| SCHEMBL31685523 | 0.72 | MAPT (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | TEAM MEDICAL, LLC | 2025-09-18 | — | — | US | claimed |
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | TEAM MEDICAL, LLC | 2025-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | SYNCRIP, SNRPA, RNASE1 | UMPS 770/4885DNPH1 2227/4885ATIC 569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.